Drug Search Results
More Filters [+]

Daporinad

Alternative Names: daporinad, apo866, fk866
Latest Update: 2023-10-05
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: NAMPT Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: TopoTarget A/S
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Daporinad

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Chronic Lymphoid Leukemia|T-Cell Cutaneous Lymphoma|T-Cell Peripheral Lymphoma|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Melanoma|Lymphoma, Non-Hodgkin|Mycosis Fungoides

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

APO866 for CTCL

P2

Completed

Lymphoma, Non-Hodgkin|T-Cell Cutaneous Lymphoma|Mycosis Fungoides|Lymphoma, B-Cell

2011-09-22

AP3001

P2

Completed

T-Cell Peripheral Lymphoma|T-Cell Cutaneous Lymphoma

2011-01-01

2006-000910-19

P2

Completed

Melanoma

2009-03-24

2006-002850-31

P2

Completed

Chronic Lymphoid Leukemia

2008-02-02

Recent News Events